- Home
- KALV vs CCBG Comparison
KALV vs CCBG Comparison
Compare KALV & CCBG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- CCBG
- Stock Information
- Founded
- KALV N/A
- CCBG 1895
- Country
- KALV United States
- CCBG United States
- Employees
- KALV N/A
- CCBG N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- CCBG Major Banks
- Sector
- KALV Health Care
- CCBG Finance
- Exchange
- KALV Nasdaq
- CCBG Nasdaq
- Market Cap
- KALV 796.4M
- CCBG 712.5M
- IPO Year
- KALV N/A
- CCBG N/A
- Fundamental
- Price
- KALV $10.95
- CCBG $43.07
- Analyst Decision
- KALV Strong Buy
- CCBG Buy
- Analyst Count
- KALV 8
- CCBG 1
- Target Price
- KALV $26.43
- CCBG $45.00
- AVG Volume (30 Days)
- KALV 1.5M
- CCBG 57.0K
- Earning Date
- KALV 09-11-2025
- CCBG 10-21-2025
- Dividend Yield
- KALV N/A
- CCBG 2.27%
- EPS Growth
- KALV N/A
- CCBG 14.00
- EPS
- KALV N/A
- CCBG 3.42
- Revenue
- KALV $1,426,000.00
- CCBG $240,944,000.00
- Revenue This Year
- KALV N/A
- CCBG $11.91
- Revenue Next Year
- KALV $213.43
- CCBG $3.57
- P/E Ratio
- KALV N/A
- CCBG $12.37
- Revenue Growth
- KALV N/A
- CCBG 8.96
- 52 Week Low
- KALV $7.30
- CCBG $32.38
- 52 Week High
- KALV $17.28
- CCBG $44.69
- Technical
- Relative Strength Index (RSI)
- KALV 27.85
- CCBG 55.64
- Support Level
- KALV $11.93
- CCBG $41.15
- Resistance Level
- KALV $12.43
- CCBG $41.94
- Average True Range (ATR)
- KALV 0.60
- CCBG 0.86
- MACD
- KALV -0.22
- CCBG -0.13
- Stochastic Oscillator
- KALV 6.17
- CCBG 55.69
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
About CCBG Capital City Bank Group
Capital City Bank Group Inc is a United States-based group engaged in Banking services, Trust and asset management services, and Brokerage services. The company operates in one segment with two principal services: Banking Services and Wealth Management Services. It offers retail and commercial banking business in the form of traditional deposit and credit services, asset management, trust, mortgage banking, merchant services, bank cards, data processing, and securities brokerage services among others through its banking offices in Florida, Georgia, and Alabama.